January | February | March | April | May | June | July | August |
| ||||||
| Deal title | Principal company | Partner company | Amount awarded ($M) | Date |
| US AMRA to award 3M funding to develop solutions for infection prevention, wound management and wound healing after traumatic injury | 3M Co. | US Army Medical Research Acquisition Activity | $34.20 | 1/10/24 |
| NIH and the Department of Defense to award Acurastem funding for amyotrophic lateral sclerosis/frontotemporal dementia research | Acurastem Inc. | National Institutes of Health and Department of Defense | $7.00 | 1/30/24 |
| BARDA to award ATCC funding to develop vaccines and therapeutics against COVID-19 | American Type Culture Collection | Biomedical Advanced Research and Development Authority | $87.00 | 1/4/24 |
| Bill & Melinda Gates Foundation to award Daré Bioscience funding to develop a live biotherapeutic against bacterial infections | Daré Bioscience Inc. | Bill & Melinda Gates Foundation Trust | $0.75 | 1/17/24 |
| Target ALS Foundation to award Dewpoint funding to evaluate the in vivo efficacy of C-mods therapeutics for TDP-43 condensatopathy in amyotrophic lateral sclerosis | Dewpoint Therapeutics Inc. | Target ALS Foundation Inc. | Payment unspecified | 1/16/24 |
| Université Paris Cité to award Hospital-University Research in Health SPRINT Consortium grant to Domain to support development of DT-7012 against cancer | Domain Therapeutics SA | Université de Paris Cité | Payment unspecified | 1/25/24 |
| Government of Wallonia to award Exo Biologics grant to develop mRNA delivery system using exosomes to encapsulate and transport SIRT6 gene | Exo Biologics SA | Walloon Region of Belgium Government | $1.67 | 1/18/24 |
| European Commission to award Fabentech funding to develop a broad-spectrum antiviral therapy to treat emerging infectious diseases | Fabentech SA | European Commission | $8.35 | 1/30/24 |
| US DoD to award Factor Bioscience funding to develop and commercialize mRNA gene-edited cell therapy candidates against Duchenne muscular dystrophy | Factor Bioscience Inc. | U.S. Department of Defense | Payment unspecified | 1/9/24 |
| KDDF to award HK inno.N funding to support the development of IN-B005 for cancer treatment | HK inno.N Corp. | Korea Drug Development Fund | Payment unspecified | 1/16/24 |
| CARB-X to award Intravacc funding to develop OMV based preventive vaccine against Neisseria gonorrhoeae infection | Intravacc BV | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $0.63 | 1/16/24 |
| Knut and Alice Wallenberg Foundation to award KI funding to develop therapies against psychosis | Karolinska Institutet | The Knut and Alice Wallenberg Foundation | $0.28 | 1/4/24 |
| CEPI to award Lemonex grant to advance Degradaball mRNA vaccine delivery against future pandemic infections | Lemonex Inc. | Coalition for Epidemic Preparedness Innovations | $4.60 | 1/4/24 |
| BARDA to award Locus Biosciences funding to develop LBP-EC01 for urinary tract infections caused by drug-resistant Escherichia coli | Locus Biosciences Inc. | U.S. Biomedical Advanced Research and Development Authority | $23.90 | 1/24/24 |
| Cystic Fibrosis Foundation to award Prime Medicine funding for preclinical research into gene editing for cystic fibrosis | Prime Medicine Inc. | Cystic Fibrosis Foundation | $15.00 | 1/25/24 |
| RSRT to award Proqr funding to develop Axiomer-based therapeutic against Rett syndrome | Proqr Therapeutics NV | Rett Syndrome Research Trust | $1.00 | 1/5/24 |
| Government of Wallonia to award Revatis funding for the research on Sarcopenia | Revatis SA | Walloon Region of Belgium Government | $1.44 | 1/18/24 |
| LLS to award Rgenta funding to develop RNA-targeting therapies against hematologic malignancies | Rgenta Therapeutics Inc. | The Leukemia & Lymphoma Society | Payment unspecified | 1/30/24 |
| Bill & Melinda Gates Foundation to award Sail Biomedicines funding to develop eRNA vaccines and monoclonal antibody therapies against malaria | Sail Biomedicines Inc. | Bill & Melinda Gates Foundation Trust | Payment unspecified | 1/3/24 |
| MTF to award Stevens Institute of Technology funding to conduct research on fabrication of multifunctional allogenic skin-derived fibrous matrices for diabetic wound repair | Stevens Institute of Technology | Musculoskeletal Transplant Foundation | Payment unspecified | 1/22/24 |
| CARB-X to award Syntiron grant to develop maternal vaccine against Escherichia coli and Klebsiella pneumoniae to prevent neonatal sepsis | Syntiron LLC | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $1.70 | 1/18/24 |
| CEPI to award HMRI funding to develop circular RNA vaccine technology against chikungunya infection | The Methodist Hospital Research Institute (d/b/a Houston Methodist Research Institute) | Coalition for Epidemic Preparedness Innovations | $3.80 | 1/25/24 |
| Lifearc to invest in University of Buea to discover therapies from AdNPB against tuberculosis, tropical diseases, viral diseases and malaria | University of Buea | Lifearc | Payment unspecified | 1/31/24 |
| Lifearc to invest in University of Ghana to enhance the discovery of antimalarials | University of Ghana | Lifearc | Payment unspecified | 1/31/24 |
| JDRF to award University of Minnesota to conduct clinical trial of sotagliflozin against type I diabetes | University of Minnesota | Juvenile Diabetes Research Foundation Ltd. | Payment unspecified | 1/22/24 |
| Boehringer Ingelheim to award Newcastle University to develop new treatments for liver cirrhosis | University of Newcastle | Boehringer Ingelheim International GmbH | $37.25 | 1/10/24 |
| Lifearc to invest in University of Stellenbosch to conduct research on the TPD using Protacs against tuberclosis | University of Stellenbosch | Lifearc | Payment unspecified | 1/31/24 |
| JDRF to award University of Toronto funding to conduct a pivotal clinical trial to test sotagliflozin to treat kidney complications in type I diabetes | University of Toronto | Juvenile Diabetes Research Foundation Ltd. | Payment unspecified | 1/22/24 |
| KFOC to award University of Toronto funding to conduct clinical trial of sotagliflozin against type I diabetes | University of Toronto | The Kidney Foundation of Canada | $1.00 | 1/22/24 |
| Carlos III Health Institute to award VHIO funding to conduct research on various diseases | Vall d'Hebron Institut d'Oncologia | Instituto de Salud Carlos III | $2.58 | 1/8/24 |
| DOD to award VUMC funding to conduct a clinical study of ketamine, vorinostat and donepezil for Rett syndrome | Vanderbilt University | US Department of Defense | $13.00 | 1/9/24 |
| BARDA to award Vaxart funding to evaluate phase IIb study of XBB vaccine against COVID-19 | Vaxart Inc. | Biomedical Advanced Research and Development Authority | $9.27 | 1/19/24 |
| MJFF to award Vesper Bio funding to evaluate the sortilin inhibition and to advance preclinical testing of therapeutics for Parkinson's disease | Vesper Bio ApS | The Michael J Fox Foundation for Parkinson's Research | $0.87 | 1/23/24 |
| German Federal Agency for Disruptive Innovations to award Aatec Medical funding for preclinical testing of ALT-105 for viral diseases of the respiratory tract | Aatec Medical GmbH | German Federal Agency for Disruptive Innovations | Payment unspecified | 2/6/2024 |
| Innovate UK to award Amply Discovery funding to improve its artificial intelligence drug discovery platform | Amply Discovery Ltd. | Innovate UK | $1.27 | 2/12/2024 |
| Innosuisse to award Amply Discovery funding to develop new artificial intelligence therapy for acute myeloid leukaemia | Amply Discovery Ltd. | Innosuisse Management AG | $0.52 | 2/12/2024 |
| Community of Madrid to award Aptatargets funding to advance the clinical development of Aptoll for acute ischemic stroke | Aptatargets SL | Community of Madrid | $2.09 | 2/19/2024 |
| DFF to award BIDMC funding to develop a personalized dendritic cell gastric cancer vaccine to prevent relapse after surgery | Beth Israel Deaconess Medical Center | DeGregorio Family Foundation | $0.50 | 2/1/2024 |
| Blacksmith Medicines to receive funding from NIAID to conduct IND-enabling and phase I studies of FG-2101 for urinary tract infections | Blacksmith Medicines Inc. | National Institute of Allergy and Infectious Diseases | $3.30 | 2/21/2024 |
| RTW Charitable Foundation to award Boston Children’s Hospital funding to develop therapies against myopathy | Boston Children's Hospital | RTW Investments LP | $0.15 | 2/12/2024 |
| MJFF to award Cantabio funding to develop DJ-1 protein therapeutic against Parkinson’s disease | Cantabio Pharmaceuticals Inc. | The Michael J Fox Foundation for Parkinson's Research | Payment unspecified | 2/6/2024 |
| CEPI and PAHO to sign a MOU to accelerate the development of vaccines against emerging infectious diseases | Coalition for Epidemic Preparedness Innovations | Pan American Health Organization | Payment unspecified | 2/6/2024 |
| ALS Association to award Coave Therapeutics fund to advance CTx-TFEB against amyotrophic lateral sclerosis | Coave Therapeutics SA | The Amyotrophic Lateral Sclerosis Association | $2.90 | 2/29/2024 |
| European Union to award consortium led by Connecta Therapeutics funding for clinical trial of AI based drug, CTH-120 for fragile X syndrome | Connecta Therapeutics | The European Union | $1.45 | 2/12/2024 |
| Cure Cancer to award Monash Biomedicine Discovery Institute grant to investigate possibility to restore the youthfulness of the cells that cause bowel cancer | Cure Brain Cancer Foundation | Monash Biomedicine Discovery Institute | $0.10 | 2/2/2024 |
| Sjöberg Foundation to award Dana-Farber Cancer Institute funding to support the development of cancer vaccine | Dana-Farber Cancer Institute Inc. | Sjoberg Foundation | $0.90 | 2/14/2024 |
| California Institute of Regenerative Medicine to award Fate Therapeutics CLIN2 grant to support phase I trial of FT-819 against systemic lupus erythematosus | Fate Therapeutics Inc. | California Institute of Regenerative Medicine | $7.90 | 2/26/2024 |
| ADDF to grant Genuv to develop artificial intelligence-based drug for Alzheimer's disease treatment | Genuv Inc. | Alzheimer's Drug Discovery Foundation | $0.60 | 2/23/2024 |
| CARB-X to award Glyprovac funding to develop GPV-02 against sepsis | Glyprovac LLC | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $0.47 | 2/29/2024 |
| CARB-X to award Harvard University funding to develop enhanced lincosamides against a range of antibiotic-resistant bacteria causing serious lower respiratory, skin and soft tissue infections | Harvard University | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $1.20 | 2/13/2024 |
| Bill & Melinda Gates Foundation to award HIPS funding to develop anti-infectives against tuberculosis and malaria | Helmholtz Institute for Pharmaceutical Research Saarland | Bill & Melinda Gates Foundation Trust | $3.10 | 2/21/2024 |
| Musella Foundation to award IB funding to advance phase I clinical trial of GaM against brain tumor | Imaging Biometrics LLC | The Musella Foundation For Brain Tumor Research & Information, Inc | $0.10 | 2/2/2024 |
| CIRM to award Immpact Bio funding for phase Ib/II study of IMPT-514 against refractory lupus nephritis and systemic lupus erythematosus | Immpact Bio USA Inc. | California Institute of Regenerative Medicine | $8.00 | 2/28/2024 |
| Alzheimer’s Association to award KI funding to evaluate SPPL-2-b inhibitor against Alzheimer's disease | Karolinska Institutet | Swedish Alzheimer Association | $0.19 | 2/20/2024 |
| Polybio Research Foundation to award Karolinska Institutet funding to conduct study on long COVID conditions | Karolinska Institutet | Polybio Research Foundation Inc. | $1.78 | 2/23/2024 |
| Swedish Research Council to award Karolinska Institutet funding to develop c-MYC protein against cancer | Karolinska Institutet | Swedish Research Council | Payment unspecified | 2/29/2024 |
| PPMD to award Kinea Bio funding to develop midi-dystrophin gene therapy against Duchenne muscular dystrophy | Kinea Bio Inc. | Parent Project Muscular Dystrophy | $0.50 | 2/13/2024 |
| CEPI to award Leniobio funding to support preclinical proof-of-concept of Alice technology platform for vaccine production | Leniobio GmbH | Coalition for Epidemic Preparedness Innovations | $2.00 | 2/8/2024 |
| Carb-X to award Limmatech Biologics funding for developing a vaccine against gonorrhea infections | Limmatech Biologics AG | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $2.20 | 2/27/2024 |
| Oregon to award Luciole matching SBIR and STTR funding to develop disease modifying therapy for Alzheimer’s disease | Luciole Pharmaceuticals | Oregon Innovation Council | Payment unspecified | 2/26/2024 |
| Polybio Research Foundation to award Mount Sinai funding to conduct a study on SARS-CoV-2 virus in Long COVID patients and HIV antivirals | Mount Sinai Health System Inc. | Polybio Research Foundation Inc. | $2.60 | 2/22/2024 |
| ALS Association to award Myrobalan Therapeutics grant to develop CSF1R inhibitor for the treatment of amyotrophic lateral sclerosis | Myrobalan Therapeutics Inc. | The Amyotrophic Lateral Sclerosis Association | $0.40 | 2/7/2024 |
| RTW Charitable Foundation to award Nationwide Children’s funding to support research on gene replacement therapy for neurodevelopmental disorder with regression, abnormal movements, loss of speech and seizures | Nationwide Children's Hospital | RTW Investments LP | $0.15 | 2/12/2024 |
| Cure Parkinson to award Olatec Therapeutics funding to support the clinical study of dapansutrile against early Parkinson’s disease | Olatec Therapeutics LLC | The Cure Parkinson's Trust | Payment unspecified | 2/20/2024 |
| Oregon INC to award PDX Pharma matching SBIR and STTR funding to develop an immunotherapy using nanoparticle codelivery for solid tumors | PDX Pharmaceuticals Inc. | Oregon Innovation Council | Payment unspecified | 2/26/2024 |
| NIH to award Perspective SBIR funding for the development of CB7-Adma for the diagnosis and treatment of cancer | Perspective Therapeutics Inc. | National Institutes of Health | $2.40 | 2/1/2024 |
| Bill & Melinda Gates Foundation to award Phaser Biomedical funding to accelerate drug discovery and development | Phaser Biomedical Ltd. | Bill & Melinda Gates Foundation Trust | $2.30 | 2/26/2024 |
| NHLBI to award Phoenix Children's Hospital funding to develop therapeutics for bronchopulmonary dysplasia in premature infants | Phoenix Children's Hospital | National Heart Lung and Blood Institute | $3.00 | 2/13/2024 |
| RTW Charitable Foundation to award Queen’s University funding to conduct research against creatine transporter deficiency | Queen's University | RTW Investments LP | $0.15 | 2/12/2024 |
| NIDA to award Sanford Burnham Prebys Medical Discovery Institute grant to support toxicology studies of SBP-9330 and phase II studies for nicotine cessation | Sanford Burnham Prebys Medical Discovery Institute | National Institute on Drug Abuse | $9.00 | 2/6/2024 |
| DTRA to Award Saponiqx and Ginkgo Bioworks MCDC contract to develop and manufacture next generation vaccine adjuvants using generative molecular design, with an option | Saponiqx Inc. | Defense Threat Reduction Agency | $31.00 | 2/15/2024 |
| LRA to award Boston Children's Hospital funding to develop therapeutics for systemic lupus erythematosus | The Children's Hospital Corp. | Lupus Research Alliance | $0.60 | 2/28/2024 |
| DOD to award Tilt Biotherapeutics funding to develop TILT-123 for treatment of ovarian cancer | Tilt Biotherapeutics | U.S. Department of Defense | $2.10 | 2/14/2024 |
| RTWCF to award University College London to conduct preclinical study on antisense oligonucleotide therapy for SPTLC1-related hereditary sensory neuropathy | University College London | RTW Investments LP | $0.15 | 2/12/2024 |
| RTWCF to award University of California to advance AAV-SPL gene therapy against sphingosine phosphate lyase insufficiency syndrome | University of California San Francisco | RTW Investments LP | $0.15 | 2/12/2024 |
| Department of Defense to award University of Miami Miller School of Medicine to conduct research on gene therapies against hearing loss | University of Miami Miller School of Medicine | US Department of Defense | $3.00 | 2/14/2024 |
| PolyBio Research Foundation to award University of Pennsylvania Perelman School funding for research on SARS-CoV-2 persistence in the gut and long COVID immune responses | University of Pennsylvania School of Medicine | Polybio Research Foundation Inc. | $2.10 | 2/23/2024 |
| RTWCF to award University of Texas Southwestern to conduct research on gene therapy against leigh syndrome | University of Texas Southwestern Medical Center | RTW Investments LP | $0.15 | 2/12/2024 |
| Innosuisse to award Vandria grant to support early clinical development plan for VNA-318 for cognitive impairment, dementia, Alzheimer’s, and Parkinson’s disease | Vandria SA | Innosuisse Management AG | $2.82 | 2/8/2024 |
| Eurostars to award Vandria grant to support pre-clinical data generation of VNA-052 against muscle disease | Vandria SA | Eurostars | $1.18 | 2/8/2024 |
| French Government to award Vivet funding to develop gene therapy for the treatment of cerebrotendinous xanthomatosis | Vivet Therapeutics SAS | French Government | $5.27 | 2/1/2024 |
| NIGMS to award WCM grant to study on cell membrane proteins involved in numerous human diseases, including genetic disorders | Weill Cornell Medicine | National Institute of General Medical Sciences | $2.70 | 2/1/2024 |
| JRF to award Aarhus University grant to conduct research on CRISPR and Cas gene editing of autologous hematopoietic stem cells for Job syndrome | Aarhus University | Job Research Foundation | $0.20 | 3/12/2024 |
| Bpifrance to award Abionyx funding to develop CER-001 for ophthalmology | Abionyx Pharma SA | EPIC Bpifrance | $1.08 | 3/14/2024 |
| CEPI to award Amplitude Therapeutics funding to conduct preclinical study on trans-amplifying mRNA vaccine | Amplitude Therapeutics Inc. | Coalition for Epidemic Preparedness Innovations | $1.00 | 3/7/2024 |
| United Kingdom Research & Innovation to award Apis Assay Technologies funding to scale up the manufacturing of Clickmers therapeutic molecules | APIS Assay Technologies Ltd. | United Kingdom Research & Innovation | Payment unspecified | 3/14/2024 |
| EC to award Aptatargets funding to initiate the Phase IIb clinical study of Aptoll in patients with ischemic stroke | Aptatargets SL | European Commission | $2.69 | 3/11/2024 |
| National Institute on Drug Abuse to award Biocorrx Pharmaceuticals funding for the development of BICX-104 for the treatment of methamphetamine use disorder | Biocorrx Pharmaceuticals Inc. | National Institute on Drug Abuse | $11.00 | 3/4/2024 |
| DoD to award Biosplice Therapeutics funding for preclinical development of Biosplice’s DYRK inhibitors in traumatic brain injury models | Biosplice Therapeutics Inc. | US Department of Defense | Payment unspecified | 3/8/2024 |
| The Michael J. Fox Foundation to award Bit.bio funding to generate cell products for research and drug discovery in Parkinson’s disease using Opti-ox technology for reprogramming of induced pluripotent stem cells | Bit.bio Ltd. | The Michael J. Fox Foundation | Payment unspecified | 3/5/2024 |
| CIRM to award CHLA funding to support development of anti-B7H3 CAR T-cell therapy to treat solid tumor | Children's Hospital Los Angeles | California Institute of Regenerative Medicine | $6.00 | 3/1/2024 |
| New Jersey Economic Development Authority to award Citius Pharmaceuticals funding to develop critical care products | Citius Pharmaceuticals Inc. | New Jersey Economic Development Authority | $2.40 | 3/7/2024 |
| California Institute for Regenerative Medicine to award City of Hope funding for the preclinical development of CLD-101 | City of Hope | California Institute for Regenerative Medicine | $5.30 | 3/11/2024 |
| National Institute of Neurological Disorders and Stroke to award Cyprium Therapeutics funding to advance AAV-ATP7A gene therapy for the treatment of Menkes disease | Cyprium Therapeutics Inc. | National Institute of Neurological Disorders and Stroke | $4.10 | 3/5/2024 |
| Cancer Focus Fund to invest and provide clinical expertise for phase I/II trial for Eisbach's EIS-12656 against refractory advanced solid tumors | Eisbach Bio GmbH | Cancer Focus Fund LP | $4.50 | 3/21/2024 |
| NIDA to award Gilgamesh Pharmaceuticals funding to develop GM-3009 against opioid use disorder | Gilgamesh Pharmaceuticals Inc. | National Institute on Drug Abuse | $14.00 | 3/14/2024 |
| Barncancerfonden to award KI funding to conduct research on the unwanted side effects from chemotherapy in childhood cancer | Karolinska Institutet | Barncancerfonden | $1.78 | 3/7/2024 |
| Swedish Kidney Foundation to award Karolinska Institutet grant to conduct research related to chronic kidney disease, dialysis and transplantation | Karolinska Institutet | Swedish Kidney Foundation | $0.32 | 3/13/2024 |
| DTRA to award Kimer Med funding for the discovery and development of antiviral drug candidates against alphaviruses | Kimer Med Ltd. | Defense Threat Reduction Agency | $0.75 | 3/7/2024 |
| NCI to award Lamassu Bio grant to develop and conduct clinical trial of SA-53 for treatment of p53 wild-type sarcomas | Lamassu Bio Inc. | National Cancer Institute | $2.05 | 3/12/2024 |
| Cancer Grand Challenges to award Massachusetts General Hospital funding to support projects MATCHMAKERS and PROSPECT for cancer research | Massachusetts Institute of Technology | Cancer Grand Challenges | $25.00 | 3/6/2024 |
| LCRF to award MD Anderson Cancer Center grant to conduct research on antibody drug conjugates targeting TROP2 and HER2 for neuroendocrine carcinomas | MD Anderson Cancer Center | Lung Cancer Research Foundation | Payment unspecified | 3/12/2024 |
| NSF to award Mellicell SBIR grant to conduct research and development work against obesity treatment | Mellicell Inc. | National Science Foundation | $0.27 | 3/28/2024 |
| Eurostars to award Neogap Therapeutics funding in a collaboration project with Okomera for the development of an analysis method for T-cell activity against a patient’s tumor | Neogap Therapeutics AB | Eurostars | $0.47 | 3/26/2024 |
| UKRI to award Nunabio funding to conduct study on DNA synthesis by oligoseed amplification with DNA polymerase enzymes | Nunabio Ltd. | United Kingdom Research & Innovation | Payment unspecified | 3/14/2024 |
| UKRI to award Oxford Simcell funding to develop vaccines against plague and urinary tract infection | Oxford Simcell Ltd. | United Kingdom Research & Innovation | Payment unspecified | 3/14/2024 |
| DTRA to award Primmune Therapeutics contract to develop PRTX-007 against Lassa fever, with an option | Primmune Therapeutics | Defense Threat Reduction Agency | $22.50 | 3/20/2024 |
| UKRI to award Prokarium funding to deliver therapeutic proteins against cancer | Prokarium | United Kingdom Research & Innovation | Payment unspecified | 3/14/2024 |
| Natural Sciences and Engineering Council of Canada to award Qu Biologics ARD grant funding to develop SSI therapies against cancer | Qu Biologics Inc. | Natural Sciences and Engineering Research Council of Canada | $0.45 | 3/11/2024 |
| UKRI to award Scarlet Therapeutics funding to conduct UNIVERCell research project to develop universal therapeutics | Scarlet Therapeutics | United Kingdom Research & Innovation | Payment unspecified | 3/14/2024 |
| Innovate U.K. to award Solascure funding to support the improvement of the ambient temperature stability of its Aurase wound gel and to optimize the release kinetics | Solascure Ltd. | Innovate U.K. | $0.51 | 3/20/2024 |
| United Kingdom Research & Innovation to award Syngensys funding to conduct research on engineered signal peptides to enhance expression levels in cell and gene therapies | Syngensys Ltd. | United Kingdom Research & Innovation | Payment unspecified | 3/14/2024 |
| CSIRO to award Telethon funding to support Spritz-OM project against otic infections | Telethon Kids Institute | Commonwealth Scientific and Industrial Research Organization | $0.50 | 3/1/2024 |
| Purdue Pharma to award University of New Mexico funding to evaluate nalmefene hydrochloride (HCl) injection for recurrent respiratory depression | The University of New Mexico | Purdue Pharma LP | Payment unspecified | 3/27/2024 |
| CGC to award Hopp Children's Cancer Center Heidelberg funding to use protein degradation strategies against children’s cancers | Universitatsklinikum Heidelberg | Cancer Grand Challenges | $25.00 | 3/6/2024 |
| Cancer Research UK to award University College London funding to develop Lungvax for lung cancer | University College London | Cancer Research UK | $2.11 | 3/22/2024 |
| LCRF to award University of Alabama at Birmingham grant to conduct research on antibody drug conjugates in lung cancer | University of Alabama at Birmingham | Lung Cancer Research Foundation | Payment unspecified | 3/12/2024 |
| LifeArc to award University of Cambridge funding to conduct a DefINe trial to repurpose generic Ferriprox for neuroferritinopathy | University of Cambridge | Lifearc | $0.93 | 3/27/2024 |
| ARPA-H to award Washington University funding to develop therapeutics against osteoarthritis | Washington University School of Medicine in St Louis | Advanced Research Projects Agency for Health | $31.00 | 3/26/2024 |
| NSF to award Weill Cornell Medicine funding to support research on RNA to discover therapeutic RNAs | Weill Cornell Medicine | National Science Foundation | $1.65 | 3/19/2024 |
| Male Contraceptive Initiative to invest in Yourchoice Therapeutics to develop YCT-529 for male contraception | Yourchoice Therapeutics | Male Contraceptive Initiative | $0.50 | 3/27/2024 |
| CIRM to award funding to develop Allogene's ALLO-316 against metastatic renal cell carcinoma | Allogene Therapeutics Inc. | California Institute of Regenerative Medicine | $15.00 | 4/26/2024 |
| CARB-X to award Basilea Pharmaceutical funding to support preclinical work on an antibiotic program | Basilea Pharmaceutical Ltd. | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) | $0.90 | 4/9/2024 |
| NIIMBL to award Batavia Biosciences funding to design a process intensification for rAAV manufacturing using HIP-Vax and chromatography technology | Batavia Biosciences Inc. | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 4/9/2024 |
| CPRIT to award Biodexa Pharmaceuticals funding to develop erapa for the treatment of familial adenomatous polyposis | Biodexa Pharmaceuticals plc | Cancer Prevention and Research Institute of Texas | $17.00 | 4/26/2024 |
| US DOD to award funding to conduct phase IIb study for Biovie's Bezisterim against long covid condition with an option | Biovie Inc. | U.S. Department of Defense | $13.10 | 4/29/2024 |
| National Cancer Institute to award Chimeron Bio a SBIR funding to develop a cancer vaccine against colorectal cancer | Chimeron Bio Corp. | National Cancer Institute | Payment unspecified | 4/16/2024 |
| NIDA to award funding to conduct study for Clear Scientific's CS-1103 against opioid dependance | Clear Scientific Inc. | National Institute on Drug Abuse | $3.04 | 4/22/2024 |
| Flanders Innovation & Entrepreneurship to award Confo Therapeutics funding to discover next-generation medicines targeting class B GPCRs using patent-protected technology platform | Confo Therapeutics NV | Flanders Innovation & Entrepreneurship | $1.72 | 4/1/2024 |
| Ministry of Science and ICT to award Curocell funding to support clinical trials for Anbal-cell against systemic lupus | Curocell Inc. | Ministry of Science and ICT | $0.79 | 4/9/2024 |
| CIRM to award Denovo Biopharma funding to conduct a phase I/II clinical study of DB-107 against high–grade glioma | Denovo Biopharma LLC | California Institute of Regenerative Medicine | $11.80 | 4/30/2024 |
| Johnson & Johnson to award Flindr Therapeutics funding to advance small molecule inhibitors against cancer | Flindr Therapeutics BV | Johnson & Johnson Innovation LLC | $21.71 | 4/30/2024 |
| Ministry of SMEs and Startups to award G2GBio grant to develop schizophrenia treatment using Innolamp drug delivery technology | G2GBio Inc | Ministry of SMEs and Startups | $8.57 | 4/30/2024 |
| IFD to award Gabather funding to conduct a phase II study of GT-002 against schizophrenia | Gabather AB (publ) | The Danish National Advanced Technology Foundation | Payment unspecified | 4/10/2024 |
| National Breast Cancer Foundation to award Garvan funding to conduct research and develop improved treatment approaches against triple-negative breast cancer | Garvan Institute of Medical Research | National Breast Cancer Foundation | Payment unspecified | 4/30/2024 |
| NHLBI to award funding to develop Geneventiv's GENV-HEM against hemophilia A or B | Geneventiv Therapeutics Inc. | National Heart Lung and Blood Institute | $2.50 | 4/16/2024 |
| Swedish Research Council to award Karolinska Institutet funding to investigate the effects of statins and ezetimibe on cholesterol against hepatocarcinogenesis | Karolinska Institutet | Swedish Research Council | $0.07 | 4/4/2024 |
| Choroideremia Research Foundation to award Kiora Pharmaceuticals funding to validate functional vision assessments for patients with profound blindness | Kiora Pharmaceuticals Inc. | Choroideremia Research Foundation | Payment unspecified | 4/11/2024 |
| Cerbios-Pharma to co-invest for Lipidor's AKP-02G2 phase III study against psoriasis | Lipidor AB | Cerbios-Pharma SA | $1.19 | 4/10/2024 |
| Unitaid to award Medincell funding for the phase I activities of long-acting injectable mdc-STM for the prevention of malaria transmission | Medincell SA | Unitaid | $6.00 | 4/9/2024 |
| NIIMBL to award Enquyst Technologies funding to study chromatography-free downstream process for producing ultra-pure monoclonal antibody using isoelectric point purification technology | Mobius Biomedical Inc. | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 4/9/2024 |
| Tour de Cure to award Noxopharm funding to conduct a preclinical study on CRO-67 for glioblastoma | Noxopharm Ltd. | Tour de Cure Pioneering Research Grant | $0.10 | 4/4/2024 |
| Bpifrance to award Ose Immunotherapeutics funding to support the registration phase III trial of Tedopi in second-line treatment in HLA-A2 positive non-small-cell lung cancer patients with secondary (acquired) resistance to anti-PD-(L)1 immunotherapy | Ose Immunotherapeutics SA | Bpifrance | $8.90 | 4/10/2024 |
| DoD to award Plus Therapeutics a funding to develop Rhenium (186 Re) obisbemeda against brain cancer | Plus Therapeutics Inc. | US Department of Defense | $3.00 | 4/22/2024 |
| NIIMBL to award Rensselaer Polytechnic Institute funding to develop surrogate antibody drug conjugates for process development and quality assessment | Rensselaer Polytechnic Institute | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 4/9/2024 |
| NIIMBL to award State University of New Jersey funding to support the production of glycosylated monoclonal antibodies | Rutgers University | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 4/9/2024 |
| French government to award Seabelife funding for Seabeeye project for geographic atrophy | Seabelife SAS | French government | $1.60 | 4/22/2024 |
| NIGMS to award Sinopia Biosciences funding to advance its computational drug discovery Learn And Discover (LEADS) platform and explore applications in oncology and immunology | Sinopia Biosciences Inc. | National Institute of General Medical Sciences | $0.35 | 4/18/2024 |
| Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to award Snipr Biome funding for the phase Ib/IIa clinical trial to test SNIPR-001 for prevention of E. coli bloodstream infections in patients with hematological cancers | Snipr Biome ApS | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $5.48 | 4/22/2024 |
| Cystic Fibrosis Foundation to award Splisense funding to continue trials for its inhaled antisense oligonucleotide drug for people with cystic fibrosis who have certain splicing mutations and potentially other rare mutations | Splisense Ltd. | Cystic Fibrosis Foundation | $8.50 | 4/4/2024 |
| Bill & Melinda Gates foundation to award Surf Bio funding to evaluate polymer formulation technology for monoclonal antibody | Surf Bio Inc. | Bill & Melinda Gates Foundation Trust | $1.60 | 4/30/2024 |
| US Department of Veterans Affairs to award a contract to TG Therapeutics' Briumvi against relapsing forms of multiple sclerosis | TG Therapeutics Inc. | U.S. Department of Veterans Affairs | $186.00 | 4/18/2024 |
| ARPA-H to award UC San Francisco funding to develop technology tissue GPS cell therapies to treat neurological diseases | University of California San Francisco | Advanced Research Projects Agency for Health | $30.00 | 4/1/2024 |
| NIIMBL to award University of Houston funding to improve measurement technologies by developing antibody mix-and-ready assays | University of Houston | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 4/9/2024 |
| CMTRF to award University of Illinois funding to support research on drug against X-linked Charcot-Marie-Tooth disease | University of Illinois at Chicago | CMT Research Foundation Inc. | Payment unspecified | 4/25/2024 |
| ERC to award VHIO funding to conduct phase Ib study for OMO-103 against metastatic pancreatic cancer | Vall d'Hebron Institut d'Oncologia | European Research Council | Payment unspecified | 4/11/2024 |
| VBI Vaccines expanded the collaboration with the Canadian Government to develop mRNA-launched enveloped virus-like particle vaccine (MLE) vaccine platform | VBI Vaccines Inc. | Government of Canada | $20.77 | 4/2/2024 |
| NIIMBL to award Virica Biotech funding to develop small molecules for the production of CAR-T cell therapies | Virica Biotech Inc. | National Institute for Innovation in Manufacturing Biopharmaceuticals | Payment unspecified | 4/9/2024 |
| NIH to award Washington University funding to develop a gene therapy against HIV | Washington University School of Medicine in St Louis | National Institutes of Health | $6.20 | 4/18/2024 |
| NCI to award funding to conduct phase I study for Alligator's mitazalimab against LAPC | Alligator Bioscience AB | National Cancer Institute | Payment unspecified | 5/14/2024 |
| CIRM to award Aspen grant to support clinical research of ANPD-001 against Parkinson's disease | Aspen Neuroscience Inc. | California Institute of Regenerative Medicine | $8.00 | 5/15/2024 |
| CEPI to award Bavarian Nordic funding for the phase II study of MVA-BN vaccine against mpox infection | Bavarian Nordic A/S | Coalition for Epidemic Preparedness Innovations | $6.50 | 5/30/2024 |
| NCI to award Bergenbio funding to conduct study for Bemcentinib in combination with Sobi's pacritinib against non-small cell lung cancer | Bergenbio ASA | National Cancer Institute | Payment unspecified | 5/28/2024 |
| CEPI to award Biontech funding to establish mRNA vaccine research and development, clinical and commercial-scale manufacturing capabilities at Biontech’s facility in Kigali, Rwanda | Biontech SE | Coalition for Epidemic Preparedness Innovations | $145.00 | 5/30/2024 |
| European Union to award Bio-Sourcing funding to develop an oral antibody treatment for inflammatory bowel disease using Biomilk platform that produces antibodies in goat milk | Bio-Sourcing | European Union | $3.70 | 5/28/2024 |
| NIGMS to award Chromatan funding to develop and integrate BioRMB single-use, column-free, counter-current elution technology for AAV manufacturing | Chromatan Inc. | National Institute of General Medical Sciences | $2.00 | 5/30/2024 |
| Brandon to award Currus Biologics funding to develop a first-in-class therapy to treat inflammatory conditions | Currus Biologics Pty Ltd. | Brandon Biocatalyst | $0.50 | 5/7/2024 |
| NCI to award Dana-Farber funding to conduct research against endometrial cancer | Dana-Farber Cancer Institute Inc. | National Cancer Institute | $15.00 | 5/6/2024 |
| Natural Sciences and Engineering Council of Canada to award Derm-Biome funding for the preclinical research activities against inflammatory diseases and aging | Derm-Biome Pharmaceuticals Inc. | Natural Sciences and Engineering Research Council of Canada | $0.45 | 5/8/2024 |
| MRA to award Drexel University funding to support development of therapies for melanoma | Drexel University | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| Brandon to award Ena Respiratory funding for the clinical development of therapeutics against viral respiratory infections | ENA Respiratory Pty Ltd. | Brandon Biocatalyst | $0.95 | 5/7/2024 |
| Melanoma Research Alliance to award Fred Hutchinson Cancer Center funding to conduct research on targeting BRAF mutated melanoma and to develop immunotherapy against melanoma | Fred Hutchinson Cancer Research Center | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| Brandon Biocatalyst to award Frontier funding to develop small molecule inhibitors involved in inflammatory diseases arising from viral respiratory infections | Frontier Inflammasome Therapeutics Pty Ltd. | Brandon Biocatalyst | $0.50 | 5/7/2024 |
| Brandon to award GPN Vaccines funding to develop a vaccine to prevent pneumococcal disease | GPN Vaccines Pty Ltd. | Brandon Biocatalyst | $0.94 | 5/7/2024 |
| GHIT to award HZI funding for the preclinical development of CorA against onchocerciasis and lymphatic filariasis | Helmholtz Zentrum fur Infektionsforschung GmbH | Global Health Innovative Technology Fund | $5.90 | 5/9/2024 |
| MRA to award Henry Ford Health System funding to support development of therapies for melanoma | Henry Ford Health System | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| Cancer Prevention and Research Institute of Texas to award Indapta Therapeutics funding to develop IDP-023 for advanced non-Hodgkin’s lymphoma and multiple myeloma | Indapta Therapeutics Inc. | Cancer Prevention and Research Institute of Texas | $4.50 | 5/21/2024 |
| FFB to award Indiana University funding to develop small molecules for PRPH2-associated retinal diseases | Indiana University | Foundation Fighting Blindness Inc. | Payment unspecified | 5/22/2024 |
| Reumatikerforbundet to award Karolinska Institutet funding for research on rheumatic diseases | Karolinska Institutet | Reumatikerförbundet | $0.63 | 5/8/2024 |
| KI researchers receive funding from the Dr Åke Olsson Foundation for hematological research | Karolinska Institutet | Dr Åke Olsson Foundation for Hematological Research | $0.12 | 5/14/2024 |
| Innovate UK to award Lift Biosciences funding to develop IMAN cell therapy variants against solid tumors and auto-immune disease | Lift Biosciences Ltd. | Innovate UK | $1.27 | 5/16/2024 |
| Michael J. Fox Foundation to award Lucy Therapeutics funding for research programs against Alzheimer’s and Parkinson's diseases and continue development of a novel drug target for Rett syndrome | Lucy Therapeutics Inc. | Michael J. Fox Foundation | $2.00 | 5/28/2024 |
| CIRM to award Luxa Biotechnology funding to conduct phase I/II study of RPESC-RPE-4W against dry age-related macular degeneration | Luxa Biotechnology LLC | California Institute of Regenerative Medicine | $4.00 | 5/1/2024 |
| NIH to award Matter Bio funding to conduct research into the information theory of aging at a genomic level, and to enable the filing of an IND and start a phase I/IIa trial in solid cancer | Matter Bio | National Institutes of Health | Payment unspecified | 5/29/2024 |
| MRA to award MSK funding to conduct research on the recombinant modified vaccinia virus Ankara for acral melanoma immunotherapy | Memorial Sloan Kettering Cancer Center | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| NIH to award Moleculin funding to conduct Phase II clinical study of WP-1066 in combination with radiation therapy for glioblastoma | Moleculin Biotech Inc. | National Institutes of Health | Payment unspecified | 5/15/2024 |
| NIH to award Mount Sinai funding to study dupilumab against alopecia areata | Mount Sinai Health System Inc | National Institutes of Health | $6.60 | 5/16/2024 |
| Bill & Melinda Gates Foundation to grant Nanite to design polymeric delivery vehicles to deliver DNA therapeutics | Nanite Inc. | Bill & Melinda Gates Foundation Trust | $1.80 | 5/8/2024 |
| Alzheimer's Association to award Neurotherapia funding to develop NTRX-07 for Alzheimer's disease | Neurotherapia Inc. | Alzheimer's Association | Payment unspecified | 5/8/2024 |
| Alberta Cancer Foundation awarded Oncobiotix a grant to support cancer and microbiome research | Oncobiotix | Alberta Cancer Foundation | $0.10 | 5/31/2024 |
| EOI Foundation to award Peptomyc funding to develop nanoemulsions for anti-MYC therapeutics against cancer | Peptomyc SL | Fundación EOI FSP | Payment unspecified | 5/2/2024 |
| Vinnova to award Pila Pharma funding to develop IP strategy for XEN-D0501 against obesity disorders | Pila Pharma AB | Vinnova | $0.01 | 5/7/2024 |
| Brandon to award Polyactiva funding to conduct phase I study on latanoprost-releasing ocular implant against glaucoma | Polyactiva Pty Ltd. | Brandon Biocatalyst | $1.50 | 5/7/2024 |
| US DOD to award Shirley Ryan Abilitylab funding to conduct phase II study for CX-1739 against spinal cord injury | Rehabilitation Institute Of Chicago | US Department of Defense | $1.55 | 5/29/2024 |
| MSCRF to award Reprocell funding to manufacture and develop human stem cell therapies | Reprocell Inc. | Maryland Stem Cell Research Fund | $0.34 | 5/14/2024 |
| US DOD to award funding to manufacture and formulate the clinical material for Respirerx's CX-1739 phase II study against spinal cord injury | Respirerx Pharmaceuticals Inc. | US Department of Defense | $0.25 | 5/29/2024 |
| Brandon to award Setonix funding to develop an oral therapy against cancer | Setonix Pharmaceuticals Pty Ltd | Brandon BioCatalyst | $0.37 | 5/7/2024 |
| GHIT Fund to award Shionogi funding to support the development of malaria prevention drugs | Shionogi & Co. Ltd. | Global Health Innovative Technology Fund | Payment unspecified | 5/9/2024 |
| MRA to award Stanford Junior University funding to conduct research on organoid model of melanoma checkpoint inhibitor response and resistance | Stanford University | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| BBSRC to award Babraham Institute funding to conduct research against epigenetics, immunology and cell signalling | The Babraham Institute | Biotechnology and Biological Sciences Research Council (BBSRC) | $60.87 | 5/13/2024 |
| NHMRC to award Burnet Institute funding to discover and develop vaccines against malaria | The Macfarlane Burnet Institute for Medical Research and Public Health | National Health and Medical Research Council | $1.91 | 5/3/2024 |
| MRA to award MGH funding to conduct research on CTLA-4 as target to optimize the management of melanoma brain metastasis | The Massachusetts General Hospital | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| NIH to award Scripps Research funding to develop molecular drivers against Alzheimer’s disease | The Scripps Research Institute | National Institutes of Health | Payment unspecified | 5/22/2024 |
| Lifearc to award MD Anderson funding to conduct research on a genetically modified HSV-1 virus in combination with SNAPvax vaccine for brain cancer in children | The University of Texas MD Anderson Cancer Center | Lifearc Pvt. Ltd. | Payment unspecified | 5/22/2024 |
| MSCRF to award Theradaptive grant to conduct human stem cell based clinical trials | Theradaptive Inc. | Maryland Stem Cell Research Fund | Payment unspecified | 5/14/2024 |
| MRA to award Thomas Jefferson University grant to support research on targeting YAP1-TEAD in acral melanoma | Thomas Jefferson University Hospitals Inc | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| NIAID to award Traverse Biotech phase I SBIR grant to develop innate immune stimulator | Traverse Biotech | National Institute of Allergy and Infectious Diseases | Payment unspecified | 5/1/2024 |
| National Cancer Institute to award Traverse Biotech funding to develop targeted immunotherapy for selected solid tumors | Traverse Biotech Inc. | National Cancer Institute | Payment unspecified | 5/1/2024 |
| VLAIO to award Universiteit Hasselt funding to develop mRNA and lipid-based nanoparticle to treat autoimmune diseases | Universiteit Hasselt | Flanders Innovation & Entrepreneurship | $1.85 | 5/21/2024 |
| Brain Cancer Canada to award UBC funding to develop bi-functional FEN1 inhibitors against GBMs | University of British Columbia | Brain Cancer Canada | $0.08 | 5/23/2024 |
| MRA to award University of California funding to support development of therapies for melanoma | University of California Los Angeles | Melanoma Research Alliance | Payment unspecified | 5/1/2024 |
| CARB-X to award University of Maryland funding to develop a maternal vaccine against neonatal sepsis | University of Maryland Medical Center | Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator | $7.92 | 5/22/2024 |
| Hidradenitis Suppurativa Foundation to award University of Miami Miller funding to support research on the role of inflammation in wound healing | University of Miami Miller School of Medicine | Hidradenitis Suppurativa Foundation | Payment unspecified | 5/15/2024 |
| CTF and DCC to award University of Miami Sylvester Comprehensive Cancer Center grant to advance treatment for neurofibromatosis | University of Miami Sylvester Comprehensive Cancer Center | Children's Tumor Foundation | $1.70 | 5/4/2024 |
| Alzheimer's Research UK to award University of Strathclyde funding to understand the link between sleep and Alzheimer’s disease | University of Strathclyde | Alzheimer's Research UK | $0.09 | 5/29/2024 |
| Stallergenes Greer Foundation to award Uppsala University funding to conduct research on mast cell progenitors against allergic asthma | Uppsala University | Stallergenes Greer Foundation | $0.03 | 5/27/2024 |
| Leukemia & Lymphoma Society to award Washington University School of Medicine grant to develop immunotherapies for different types of leukemia | Washington University School of Medicine in St Louis | The Leukaemia and Lymphoma Society | $5.00 | 5/11/2024 |
| MJFF to award Alchemab Therapeutics funding to support its Parkinson’s disease program | Alchemab Therapeutics Ltd. | The Michael J. Fox Foundation for Parkinson’s Research | $0.59 | 6/7/2024 |
| CF AMR Syndicate to award Bioversys funding to support the development of small molecules targeting difficult to treat non-tubercular mycobacteria lung disease in people with cystic fibrosis | Bioversys AG | CF AMR Syndicate | $0.63 | 6/4/2024 |
| CF AMR Syndicate to award Bioversys funding to develop small molecules against non-tubercular mycobacteria lung disease with cystic fibrosis | Bioversys AG | CF AMR Syndicate | $0.63 | 6/4/2024 |
| Innovate UK to award Bivictrix funding to support the preclinical development of BVX-002 for ovarian cancer | Bivictrix Therapeutics plc | Innovate UK | $0.37 | 6/6/2024 |
| KDDF to award CHA Biotech grant to support research and development of CBT-101 against recurrent glioblastoma | CHA Bio & Diostech Co. Ltd. | Korea Drug Development Fund | Payment unspecified | 6/24/2024 |
| Sanofi to award Ctiobiotech funding to support the SAFESKIN3D project for the better prediction of vaccine tolerance at early stages of development | Ctiobiotech | Sanofi SA | $0.54 | 6/26/2024 |
| BARDA to award funding to conduct phase IIb study for Cyanvac's CVXGA against coronavirus disease 19 infection | Cyanvac LLC | Biomedical Advanced Research and Development Authority | Payment unspecified | 6/13/2024 |
| US DoD to award Delix Therapeutics funding to advance development of DLX-001 against hearing loss | Delix Therapeutics Inc. | U.S. Department of Defense | $0.82 | 6/4/2024 |
| BARDA to award Edesa Biotech funding to evaluate phase II clinical study of paridiprubart in acute respiratory distress syndrome patients | Edesa Biotech Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 6/24/2024 |
| Eureka Eurostars funding program, the Icelandic Technology Development Fund, and Innosuisse in Switzerland to award Epiendo Pharmaceuticals and Alveolix funding to develop a treatment for ulcerative colitis | Epiendo Pharmaceuticals ehf and Alveolix AG | Eureka Eurostars, the Icelandic Technology Development Fund, and Innosuisse | $1.52 | 6/5/2024 |
| Gates Foundation to award Ethris' funding to advance the development of ETH-47 against a broad spectrum of chronic respiratory diseases and respiratory infections | Ethris GmbH | Bill & Melinda Gates Foundation Trust | $5.00 | 6/18/2024 |
| NIAID to award FASI P01 grant funding to support a neuroimmunology research program for food allergies | Food Allergy Science Initiative Inc. | National Institute of Allergy and Infectious Diseases | $11.60 | 6/6/2024 |
| Government of Wallonia to award Genflow Biosciences funding to advance exosome-based therapies against liver fibrosis and Werner Syndrome | Genflow Biosciences plc | Walloon Region of Belgium Government | $0.43 | 6/12/2024 |
| Hong Kong Science and Technology Parks to award Immuno Cure Biotech funding to develop DNA vaccine and antibody immunotherapies for infectious diseases, inflammatory diseases, and cancers | Immuno Cure Biotech Ltd. | Hong Kong Science and Technology Parks Corp. | Payment unspecified | 6/26/2024 |
| Parkinson’s UK to award Imperial College London a funding to support the development of new drug for Parkinson’s disease | Imperial College London | Parkinson's UK | $0.13 | 6/28/2024 |
| LifeArc to award IITR funding to discover antibodies that can improve drug delivery against dengue fever | Indian Institute Of Technology Roorkee | Lifearc Pvt. Ltd. | $0.22 | 6/11/2024 |
| BARDA to award Inflarx funding to evaluate vilobelimab for acute respiratory distress syndrome | Inflarx GmbH | Biomedical Advanced Research and Development Authority | Payment unspecified | 6/24/2024 |
| US DOD to award contract to Just – Evotec to develop an accelerated mAb development and manufacturing solution for the DOD’s manufacturing optimization program | Just - Evotec Biologics Inc. | US Department of Defense | $39.00 | 6/25/2024 |
| CIMED to award KI funding to conduct research on various therapeutics and diagnostics for different diseased conditions | Karolinska Institutet | Centre for Innovative Medicine | Payment unspecified | 6/20/2024 |
| Swedish Heart Lung Foundation to award KSAC funding to advance research on drugs against allergic asthma | Karolinska University Hospital | Swedish Heart Lung Foundation | $1.44 | 6/3/2024 |
| NIAID to award KBio grant to conduct phase I trial of EV68-228 against enterovirus D68 infection | KBio | National Institute of Allergy and Infectious Diseases | Payment unspecified | 6/27/2024 |
| The US DOD to award funding to conduct study for Kevirx's KVX-053 against acute lung injury/acute respiratory distress syndrome | Kevirx Inc. | US Department of Defense | $1.99 | 6/11/2024 |
| Innovate UK to award Nuclera funding for the development of eprotein discovery platform | Nuclera Nucleics Ltd. | Innovate UK | $1.45 | 6/7/2024 |
| Foundation Fighting Blindness to award funding to Opus Genetics for the advancement of two preclinical candidate programs | Opus Genetics Inc. | Foundation Fighting Blindness Inc | $1.70 | 6/13/2024 |
| Bill & Melinda Gates Foundation to award Partitionbio funding to support biologics shuttle platform for therapeutic nucleic acids delivery | Partitionbio | Bill & Melinda Gates Foundation Trust | Payment unspecified | 6/17/2024 |
| CSRDC to award Plantform funding to develop oral vaccine to protects swine herds against porcine epidemic diarrhea virus | Plantform Corp. | Swine Innovative Porc | $0.34 | 6/17/2024 |
| ALS Association to award funding to conduct study for Projenx's prosetin against amyotrophic lateral sclerosis | Projenx Inc. | The Amyotrophic Lateral Sclerosis Association | $1.00 | 6/20/2024 |
| NIMH to award funding to develop Rumi's BRD9 siRNA against autism | Rumi Scientific Holdings Inc. | The National Institute of Mental Health | $1.90 | 6/3/2024 |
| ADHS to award SRI grant to support phase I/ II trial of psilocybin mushrooms against life threatening illnesses | Scottsdale Research Institute | Arizona Department of Health Services | Payment unspecified | 6/18/2024 |
| Maryland Stem Cell Research Fund to award Seraxis funding to develop allogenetically compatible pancreatic islet replacement therapy for type 1 diabetes | Seraxis Inc. | Maryland Stem Cell Research Fund | $0.40 | 6/20/2024 |
| CMTRF to award Revir Therapeutics funding to develop small molecule therapeutics against Charcot Marie Tooth type 1 disease | Shenzhen Revir Therapeutics Co. Ltd. | CMT Research Foundation Inc. | Payment unspecified | 6/19/2024 |
| Milliporesigma to award funding to develop Siren's universal AAV immuno-gene therapy against cancer | Siren Biotechnology Inc. | Milliporesigma | Payment unspecified | 6/4/2024 |
| Bill & Melinda Gates Foundation to award funding to develop Snipr Biome's SNIPR-001 against environmental enteric dysfunction | Snipr Biome ApS | Bill & Melinda Gates Foundation Trust | Payment unspecified | 6/28/2024 |
| Queensland government to award the University of Queensland funding to improve the quality of mRNA therapies | The University of Queensland | Queensland Government | $0.74 | 6/27/2024 |
| Tiziana Life Sciences received nondilutive funding to support its ongoing phase II trial of intranasal foralumab in non-active secondary progressive multiple sclerosis as well as in Alzheimer’s disease. | Tiziana Life Sciences Ltd. | $3.40 | 6/28/2024 | |
| Bill & Melinda Gates Foundation to award MARBIO grant to develop a self injectable contraceptive formulation for women | Undisclosed | Bill & Melinda Gates Foundation Trust | Payment unspecified | 6/13/2024 |
| V Foundation to award UMMSM funding to conduct combination study of CAR-T therapy with mosunetuzumab and polatuzumab against lymphoma | University of Miami Miller School of Medicine | V Foundation for Cancer Research | $0.20 | 6/27/2024 |
| V Foundation to award UMMSM funding to study BRCA related genes mutations against pancreatic cancer | University of Miami Miller School of Medicine | V Foundation for Cancer Research | $0.66 | 6/27/2024 |
| V Foundation to award Sylvester Cancer Center funding to research on links between DUOX2 expression to inflammation and CRC | University of Miami Sylvester Comprehensive Cancer Center | V Foundation for Cancer Research | $0.80 | 6/27/2024 |
| V Foundation to award University of Miami Sylvester Comprehensive Cancer Center grant to support research on cancer cell mutations | University of Miami Sylvester Comprehensive Cancer Center | V Foundation for Cancer Research | $0.20 | 6/27/2024 |
| Dynami Foundation to award University of Michigan grant to support research and develop treatments for lobular breast cancer | University of Michigan | Dynami Foundation | $0.30 | 6/27/2024 |
| Pitt Hopkins Research Foundation to award Unravel Biosciences funding to conduct clinical study of RVL-001 against Pitt Hopkins syndrome | Unravel Biosciences Inc. | Pitt Hopkins Research Foundation | Payment unspecified | 6/11/2024 |
| BARDA to award Vaxart funding to conduct a phase 2b study of oral pill COVID-19 vaccine | Vaxart Inc. | Biomedical Advanced Research and Development Authority | $453.00 | 6/13/2024 |
| Wellcome Trust to award Alto funding to conduct a phase IIb clinical study of ALTO-100 in patients with bipolar depression | Alto Neuroscience Inc. | The Wellcome Trust Ltd. | $11.70 | 7/25/2024 |
| NIDA to award Anebulo Pharmaceuticals funding to develop selonabant against CNS depression | Anebulo Pharmaceuticals Inc. | National Institute on Drug Abuse | $1.90 | 7/22/2024 |
| Government of Canada invests in Aspect’s tissue therapeutic platform, and pipeline of bioprinted tissue therapeutics for metabolic and endocrine diseases | Aspect Biosystems Ltd. | Federal Government of Canada | $72.75 | 7/10/2024 |
| Canadian Institutes of Health Research to award Bavarian Nordic funding to support post-exposure vaccination of MVA-BN against mpox infection | Bavarian Nordic A/S | Canadian Institutes of Health Research | $4.90 | 7/28/2024 |
| CEPI to invest in Manguinhos to support vaccine production against infectious disease | Bio-Manguinhos/Fiocruz | Coalition for Epidemic Preparedness Innovations | $17.90 | 7/29/2024 |
| Australian Melanoma Research Foundation to award Centenary Institute funding to conduct research against melanoma | Centenary Institute Cancer Medicine & Cell Biology | Australian Melanoma Research Foundation | $0.01 | 7/16/2024 |
| French Government to award funding to develop Crossject's Zeneo against allergic reactions | Crossject SA | French Government | $7.43 | 7/10/2024 |
| 65LAB to award Duke-NUS Medical School grant to develop therapeutics against inflammatory diseases | Duke-NUS Medical School | 65LAB Pte. Ltd. | $1.85 | 7/29/2024 |
| U.S. Government to award Emergent Biosolutions funding to supply Vaccinia Immune Globulin Intravenous (VIGIV) for smallpox preparedness | Emergent Biosolutions Inc. | U.S. Government | $122.90 | 7/2/2024 |
| U.S. Government to award Emergent Biosolutions funding to supply Cyfendus for anthrax | Emergent Biosolutions Inc. | U.S. Government | $30.00 | 7/2/2024 |
| U.S. Government to award Emergent Biosolutions funding to supply ACAM-2000 for smallpox | Emergent Biosolutions Inc. | U.S. Government | $99.90 | 7/2/2024 |
| NHLBI to award Genexys BioMed Phase I SBIR funding to support the development of non-viral, non-lipid delivery platform | Genexys BioMed | National Heart Lung and Blood Institute | $0.32 | 7/30/2024 |
| ARPA-H to award funding to develop Harvard University's agnostic RNA therapeutic against cancer and infectious diseases | Harvard University | The Advanced Research Projects Agency for Health | $27.00 | 7/15/2024 |
| MJFF to award Herantis grant to support phase Ib trial of HER-096 against Parkinson disease | Herantis Pharma plc | The Michael J Fox Foundation for Parkinson's Research | $3.87 | 7/1/2024 |
| NIH to award Mount Sinai funding to investigate JAK inhibition for alopecia areata and atopic dermatitis in people with Down syndrome | Icahn School of Medicine at Mount Sinai | National Institutes of Health | $4.00 | 7/11/2024 |
| European Innovation Council to award Impact Biotech funding to advance Padeliporfin VTP through its ongoing Phase 3 ENLIGHTED trial in low-grade upper tract urothelial cancer | Impact Biotech Ltd. | European Innovation Council | $2.71 | 7/24/2024 |
| MJFF to award Kannalife Sciences funding to develop KLS-13019 targeting neuroinflammation and mitochondrial dysfunction | Kannalife Sciences Inc. | The Michael J. Fox Foundation for Parkinson's Research | $1.49 | 7/2/2024 |
| MJFF to award Lario Therapeutics funding for the preclinical study of selective CaV2.3 calcium channel against Parkinson’s disease | Lario Therapeutics Ltd. | The Michael J Fox Foundation for Parkinson's Research | $6.00 | 7/22/2024 |
| Brain Canada to award McGill University funding to develop a therapeutic against insomnia and neuropathic pain | McGill University | Brain Canada Foundation | $0.45 | 7/3/2024 |
| CQDM to award McGill University funding to develop a therapeutic against insomnia and neuropathic pain | McGill University | CQDM | $0.66 | 7/3/2024 |
| EIC to award funding to develop Mediwound's Escharex against diabetic foot ulcers | Mediwound Ltd. | European Commission | $2.69 | 7/16/2024 |
| MJFF and Parkinson's UK to award Mission Therapeutics funding to develop MTX-325 for early-stage Parkinson's disease | Mission Therapeutics Ltd. | The Michael J. Fox Foundation for Parkinson's Research and Parkinson's UK | $5.20 | 7/2/2024 |
| BARDA to award Moderna funding to develop mRNA based pandemic influenza vaccines against H5 influenza viral infection | Moderna Inc. | Biomedical Advanced Research and Development Authority | $176.00 | 7/2/2024 |
| Greg Marzolf Jr. Foundation to award Myogenica funding for IND enabling studies of MyoPAXon against DMD | Myogenica Inc. | Greg Marzolf Jr Foundation | Payment unspecified | 7/17/2024 |
| CIRM to award Nexcella funding to support phase Ib/II clinical study of NXC-201 for relapsed/refractory AL amyloidosis | Nexcella Inc. | California Institute of Regenerative Medicine | $8.00 | 7/25/2024 |
| EU to award Olatec funding to conduct DAPAN-DIA trial on dapansutrile for T2D and diabetes-related complications | Olatec Therapeutics LLC | The European Union | Payment unspecified | 7/11/2024 |
| European Innovation Council to award Pharmnovo funding to advance PN-6047 through a phase IIa proof-of-concept study | Pharmnovo AB | European Innovation Council | $2.70 | 7/16/2024 |
| Bpifrance to award PK MED funding to advance the development of PKM-02 for bone marrow transplantation in leukemias and hemoglobinopathies | PK MED SAS | Bpifrance | $1.61 | 7/24/2024 |
| US DOD to award funding to develop Recce Pharmaceuticals' R-327 gel against wound healing | Recce Pharmaceuticals Ltd. | US Department of Defense | $2.00 | 7/16/2024 |
| MOTIE to award Recerise funding to support the development of tailored targeted therapies for refractory cancer | Recerise Therapeutics | Republic of Korea Ministry of Trade,Industry & Energy | $2.88 | 7/1/2024 |
| CIRM to award Rejuvenate Bio funding to develop RJB-0402 against desmoplakin gene variant arrhythmogenic cardiomyopathy | Rejuvenate Bio Inc. | California Institute of Regenerative Medicine | $4.00 | 7/1/2024 |
| BARDA to award RenBio funding to evaluate DNA-based delivery of antiviral antibodies for Zika and influenza prevention | Renbio Inc. | Biomedical Advanced Research and Development Authority | $0.75 | 7/25/2024 |
| The Wellcome Trust to award RenBio funding to evaluate DNA-based delivery of antiviral antibodies for Zika and influenza prevention | Renbio Inc. | The Wellcome Trust Ltd | $2.90 | 7/25/2024 |
| Four Diamonds Foundation to award Senhwa Biosciences funding to support silmitasertib clinical trials for solid tumor | Senhwa Biosciences Inc. | Four Diamonds Foundation. | Payment unspecified | 7/11/2024 |
| CIRM to award funding to conduct phase I study for Senti Bio's SENTI-202 against hematologic malignancies | Senti Biosciences Inc. | California Institute of Regenerative Medicine | $8.00 | 7/1/2024 |
| Lupus Foundation to award Boston Children's Hospital funding to conduct research against SLE in children | The Children's Hospital Corp | The Lupus Foundation of America Inc | Payment unspecified | 7/23/2024 |
| MRC to award FCI funding to conduct research on complex secretory processes | The Francis Crick Institute Ltd. | Medical Research Council | $1.51 | 7/25/2024 |
| Lupus Foundation to award University of Pennsylvania funding to conduct research against SLE in children | The University of Pennsylvania | The Lupus Foundation of America Inc | Payment unspecified | 7/23/2024 |
| BARDA to award funding to develop Tiba Biotech's RNA therapeutics against influenza | Tiba Biotech LLC | Biomedical Advanced Research and Development Authority | $0.75 | 7/11/2024 |
| DTRA to award Tonix Pharmaceuticals funding to develop TNX-4200 for medical countermeasures | Tonix Pharmaceuticals Holding Corp. | Defense Threat Reduction Agency | $34.00 | 7/1/2024 |
| NIH to award Trethera funding for the preclinical development of TRE-515 against pediatric acute disseminated encephalomyelitis | Trethera Corp. | National Institute for Health | $2.00 | 7/16/2024 |
| Queensland Government to award Uniquest funding to conduct research, discover, develop and commercialize small molecule therapeutics | Uniquest Pty Ltd. | Queensland Government | $2.00 | 7/31/2024 |
| NIHR to award University Of Bristol funding to study OTC nasal sprays against flu and colds | University of Bristol | National Institute for Health and Care Research | Payment unspecified | 7/12/2024 |
| FSR to award University of California funding to conduct research against neurosarcoidosis | University of California San Francisco | Foundation for Sarcoidosis Research | $0.15 | 7/24/2024 |
| V Foundation for Cancer Research to award Sylvester Comprehensive Cancer Center funding to conduct research on molecular and therapeutic assessment of STAT3-driven T-cell malignancies | University of Miami Miller School of Medicine | V Foundation for Cancer Research | $0.20 | 7/11/2024 |
| Department of Defense to award University of Minnesota funding for IND enabling studies of MyoPAXon against DMD | University of Minnesota | US Department of Defense | Payment unspecified | 7/17/2024 |
| NIAMS to award University of Minnesota funding to conduct IND enabling studies of MyoPAXon against DMD | University of Minnesota | National Institute of Arthritis and Musculoskeletal and Skin Diseases | Payment unspecified | 7/17/2024 |
| Duchenne Uk to award University of Minnesota funding to conduct IND enabling studies of MyoPAXon against DMD | University of Minnesota | Duchenne UK | $0.90 | 7/17/2024 |
| CEPI amended the existing partnership agreement with Valneva to provide additional funding up to $41.3M over the next five years to expand access to Ixchiq | Valneva SE | Coalition for Epidemic Preparedness Innovations | $41.30 | 7/22/2024 |
| NIAID to award Vaxcyte, University of North Carolina and University of Chicago to develop vaccine for Chlamydia | Vaxcyte Inc. | National Institute of Allergy and Infectious Diseases | $9.50 | 7/31/2024 |
| NIAID to award Versatope phase II SBIR funding to develop a bi-specific malarial vaccine | Versatope Therapeutics Inc. | National Institute of Allergy and Infectious Diseases | $3.00 | 7/29/2024 |
| BARDA to award Walgreen funding to conduct phase IV study on vaccines against COVID-19 infections | Walgreen Co. | Biomedical Advanced Research and Development Authority | $25.00 | 7/23/2024 |
| NIAID to award WCM funding to develop treatment regimens for tuberculosis | Weill Cornell Medicine | National Institute of Allergy and Infectious Diseases | $31.00 | 7/8/2024 |
| NIAID to award Anivive funding to develop a vaccine against Coccidioides infection | Anivive Lifesciences Inc. | National Institute of Allergy and Infectious Diseases | $33.00 | 8/2/2024 |
| CEPI to award Boost Biopharma funding to advance the antigen construct to quickly develop vaccines against COVID-19 | Boost Biopharma Inc. | Coalition for Epidemic Preparedness Innovations | $5.00 | 8/2/2024 |
| NIH to award Boost Biopharma funding to support a phase I clinical study of COVID-19 vaccine | Boost Biopharma Inc. | National Institutes of Health | Payment unspecified | 8/2/2024 |
| NIH to award BITT grant to support the ongoing Phase I clinical trial of BIR-2101 against cancer | Boston Immune Technologies & Therapeutics Inc | National Institutes of Health | $4.00 | 8/16/2024 |
| FLF to award Dana-Farber Cancer Institute funding to support projects for follicular lymphoma | Dana-Farber Cancer Institute Inc. | Follicular Lymphoma Foundation | Payment unspecified | 8/7/2024 |
| MAPS to award Emory University funding to examine MDMA-assisted massed exposure therapy for post-traumatic stress disorder | Emory University | Multidisciplinary Association for Psychedelic Studies | $0.20 | 8/27/2024 |
| ARPA-H to award funding to develop EnPlusOne's RNA therapeutic against cancer and infectious diseases | Enplusone Biosciences Inc. | Advanced Research Projects Agency for Health | $27.00 | 8/15/2024 |
| BMGF to award funding to conduct study for Immorna's JCXH-108 against RSV infection | Immorna Biotherapeutics Inc. | Bill & Melinda Gates Foundation Trust | Payment unspecified | 8/26/2024 |
| Breakthrough to award Insphero funding to develop therapeutics against type 1 diabetes | Insphero AG | Breakthrough T1D | Payment unspecified | 8/19/2024 |
| Swedish Research Council to award KI funding to develop cholinesterase inhibitors against Alzheimers disease and Dementia with Lewy bodies | Karolinska Institutet | Swedish Research Council | Payment unspecified | 8/23/2024 |
| NIH to award funding to conduct phase I study for Marker's MT-601 against NHL | Marker Therapeutics Inc. | National Institutes of Health | $2.00 | 8/12/2024 |
| Department of Defense to award funding to MAUI Imaging to support trauma medicine across four branches of the military | Maui Imaging Inc. | US Department of Defense | $4.00 | 8/22/2024 |
| Food Allergy Fund to award Mount Sinai funding to repurpose FDA-approved drug for the prevention and treatment of food allergies | Mount Sinai Health System Inc. | The Food Allergy Fund | Payment unspecified | 8/6/2024 |
| CMTRF to award Nationwide Children’s Hospital funding to develop vehicles for delivering gene therapies against Charcot-Marie-Tooth disease | Nationwide Children's Hospital | CMT Research Foundation Inc. | Payment unspecified | 8/13/2024 |
| US DOD to award NMRC funding to develop Travelan against diarrhea | Naval Medical Research Command | US Department of Defense | $2.30 | 8/16/2024 |
| Food Allergy Fund to award Northwestern University funding to repurpose FDA-approved drug for the prevention and treatment of food allergies | Northwestern University | The Food Allergy Fund | Payment unspecified | 8/6/2024 |
| Austrian Research Promotion Agency to award Quantro Therapeutics funding to advance transcriptomic discovery platform to an industrial level | Quantro Therapeutics GmbH | Austrian Research Promotion Agency | $1.85 | 8/6/2024 |
| BARDA to award funding to conduct preclinical study for Red Queen's RQ-01 against influenza | Red Queen Therapeutics Inc. | Biomedical Advanced Research and Development Authority | Payment unspecified | 8/6/2024 |
| Japanese AMED to award Shinobi grant to support development of NJA-003 against solid tumors | Shinobi Therapeutics Inc. | Japan Agency for Medical Research and Development | $59.00 | 8/6/2024 |
| ScaleReady to award Stanford Medicine funding to support the development of G-Rex platform for CAR-T cell therapy manufacturing | Stanford Medicine | Scaleready LLC | $0.30 | 8/27/2024 |
| Unitaid to award Swipha funding to support the production of sulfadoxine-pyrimethamine for malaria | Swiss pharma Nigeria Ltd. | UNITAID | Payment unspecified | 8/21/2024 |
| Innovate UK to award Synaptixbio funding to conduct clinical study of anti-TUBB4A gene therapy against leukodystrophy | Synaptixbio Ltd. | Innovate UK | $2.52 | 8/22/2024 |
| NIH to award MGH funding to study the effects of low-dose carbon monoxide against PD | The Massachusetts General Hospital | National Institutes of Health | Payment unspecified | 8/22/2024 |
| CPRIT to award MD Anderson cancer center funding to support cancer research | The University of Texas MD Anderson Cancer Center | Cancer Prevention and Research Institute of Texas | $9.20 | 8/21/2024 |
| SUTC to award Great Ormond Street Institute of Child Health grant to support clinical trial to test treatment combination for neuroblastoma | UCL Great Ormond Street Institute of Child Health | Stand Up To Cancer | $4.73 | 8/7/2024 |
| CIHR to award University of Calgary funding to support the PONTIAC phase II trial of Cilastatin against AKI | University of Calgary | Canadian Institutes of Health Research | $1.50 | 8/2/2024 |
| Cancer Research Horizons to award University of Cambridge grant to develop superkiller CAR-T cell therapy for colorectal and liver cancers | University of Cambridge | Imperial Cancer Research Technology Ltd | Payment unspecified | 8/13/2024 |
| Follicular Lymphoma Foundation to award Wake Forest Levine Cancer funding to develop therapies against MCL and tFL | Wake Forest Baptist Health | Follicular Lymphoma Foundation | Payment unspecified | 8/7/2024 |